Theresa Wicklin Gillespie

Learn More
Prostate cancer remains the second leading cause of cancer death in American men and there is an unmet need for biomarkers to identify patients with aggressive disease. In an effort to identify biomarkers of recurrence, we performed global RNA sequencing on 106 formalin-fixed, paraffin-embedded prostatectomy samples from 100 patients at three independent(More)
Author's disclosures of potential conflict of interest are found at the end of this article. C linical trials in oncology continue to offer hope for tumor control. Such hope intensifies as the rapidly advancing knowledge from molecular biology, genetics, and immunology is more readily applied to targeted therapies. The ability to discern genomic or genetic(More)
Purpose: Medical gender confirmation therapy (GCT) plays an important role in transgender health; however, its prevalence and determinants constitute an area of uncertainty. Methods: Data for this cross-sectional study were obtained from an online survey distributed from October 2012 through the end of 2013 among persons who visited the social media sites(More)
This paper outlines the design process and challenges of creating a character for our implementation of an embodied conversational agent (ECA), specifically integrating diverse views from focus groups consisting of individuals representing different levels of socioeconomic status and health literacy. Initial focus groups consisting of members from both(More)
Pr ecis: The robust antitumor properties of B-Raf kinase inhibitors appear to relate to an ability to correct immune escape, suggesting new uses for these drugs in cancer treatment through combination with active immunotherapies. Pr ecis: These findings define a microRNA that potently activates p53 and suppresses ribosome biogenesis, defining a novel core(More)
ated for an underlying cause for her anemia. Her history of menstrual blood loss was not impressive, and she denied mele-na. The oral iron exacerbated her constipation , thus she was unable to obtain stool samples for fecal occult blood testing. She was changed to intramuscular iron dex-tran, given as 1 mL (50 mg) into each buttock each week (via Z-track(More)
About this Publication This newsletter is the second in a series designed to educate oncology nurses and health care professionals regarding the use of molecular and targeted therapies in the treatment of cancer. The newsletter series is planned and developed by Oncology Education Services, Inc. (OES) and supported through an unrestricted educational grant(More)
  • 1